Laitman Y, Niskakoski A, Bernstein-Molho R, Koskinen L, Rabina D, Koskenvuo J
Breast Cancer Res Treat. 2024; 208(3):589-595.
PMID: 39102164
PMC: 11522137.
DOI: 10.1007/s10549-024-07454-z.
Kwong A, Ho C, Au C, Ma E
Cancers (Basel). 2024; 16(14).
PMID: 39061189
PMC: 11274758.
DOI: 10.3390/cancers16142547.
Shao B, Di L
Oncol Lett. 2024; 27(6):253.
PMID: 38646498
PMC: 11027096.
DOI: 10.3892/ol.2024.14387.
Setton J, Selenica P, Mukherjee S, Shah R, Pecorari I, McMillan B
NPJ Breast Cancer. 2021; 7(1):135.
PMID: 34635660
PMC: 8505423.
DOI: 10.1038/s41523-021-00339-0.
Vietri M, Caliendo G, DElia G, Resse M, Casamassimi A, Minucci P
Genes (Basel). 2020; 11(12).
PMID: 33287145
PMC: 7761639.
DOI: 10.3390/genes11121451.
Literature Review of as a Cancer Predisposing Gene with a Focus on Breast and Ovarian Cancers.
Alenezi W, Fierheller C, Recio N, Tonin P
Genes (Basel). 2020; 11(8).
PMID: 32726901
PMC: 7464855.
DOI: 10.3390/genes11080856.
Association between hereditary predisposition to common cancers and congenital multimalformations.
Kwiatkowski F, Perthus I, Uhrhammer N, Francannet C, Arbre M, Bidet Y
Congenit Anom (Kyoto). 2019; 60(1):22-31.
PMID: 30785647
PMC: 6973007.
DOI: 10.1111/cga.12329.
Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
Rebbeck T, Friebel T, Friedman E, Hamann U, Huo D, Kwong A
Hum Mutat. 2018; 39(5):593-620.
PMID: 29446198
PMC: 5903938.
DOI: 10.1002/humu.23406.
Double Heterozygosity for BRCA1 Pathogenic Variant and BRCA2 Polymorphic Stop Codon K3326X: A Case Report in a Southern Italian Family.
Palmirotta R, Lovero D, Stucci L, Silvestris E, Quaresmini D, Cardascia A
Int J Mol Sci. 2018; 19(1).
PMID: 29346284
PMC: 5796231.
DOI: 10.3390/ijms19010285.
Mutational analysis of and genes in Peruvian families with hereditary breast and ovarian cancer.
Buleje J, Guevara-Fujita M, Acosta O, Huaman F, Danos P, Murillo A
Mol Genet Genomic Med. 2017; 5(5):481-494.
PMID: 28944232
PMC: 5606899.
DOI: 10.1002/mgg3.301.
Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women.
Rebbeck T, Friebel T, Mitra N, Wan F, Chen S, Andrulis I
Breast Cancer Res. 2016; 18(1):112.
PMID: 27836010
PMC: 5106833.
DOI: 10.1186/s13058-016-0768-3.
Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population.
Lavie O, Narod S, Lejbkowicz F, Dishon S, Goldberg Y, Gemer O
Ann Oncol. 2010; 22(4):964-966.
PMID: 20924075
PMC: 3065879.
DOI: 10.1093/annonc/mdq460.
Identification of a Danish breast/ovarian cancer family double heterozygote for BRCA1 and BRCA2 mutations.
Steffensen A, Jonson L, Ejlertsen B, Gerdes A, Nielsen F, Hansen T
Fam Cancer. 2010; 9(3):283-7.
PMID: 20455026
PMC: 2921502.
DOI: 10.1007/s10689-010-9345-6.
Phenocopies in BRCA1 and BRCA2 families: evidence for modifier genes and implications for screening.
Smith A, Moran A, Boyd M, Bulman M, Shenton A, Smith L
J Med Genet. 2006; 44(1):10-15.
PMID: 17079251
PMC: 2597903.
DOI: 10.1136/jmg.2006.043091.
The genetic epidemiology of breast cancer genes.
Thompson D, Easton D
J Mammary Gland Biol Neoplasia. 2004; 9(3):221-36.
PMID: 15557796
DOI: 10.1023/B:JOMG.0000048770.90334.3b.
Hereditary breast cancer in Jews.
Rubinstein W
Fam Cancer. 2004; 3(3-4):249-57.
PMID: 15516849
DOI: 10.1007/s10689-004-9550-2.
